Wall Street Zen Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

A number of other research firms also recently commented on REGN. Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Trading Up 2.9%

Shares of REGN stock opened at $781.60 on Friday. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average price is $770.83 and its 200-day moving average price is $690.73. The stock has a market capitalization of $82.63 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 2.04 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company earned $12.07 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock worth $4,142,738 in the last ninety days. 7.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. WPG Advisers LLC lifted its holdings in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.